Skip to main content

Outcome of Treatment for Osteosarcoma of the Extremities Over the Last 20 Years: Report from 11 Referral Centers in Japan

  • Chapter
  • First Online:
Osteosarcoma

Abstract

The survival of patients with osteosarcoma has improved dramatically due to the introduction of effective systemic chemotherapy. The key standard drugs for osteosarcoma chemotherapy are methotrexate, doxorubicin, and cisplatin, and multi-institutional trials based on these drugs have been conducted in Japan since the 1990s. However, there have been no nationwide data on treatment outcome, especially with regard to survival and prognostic factors. In this chapter, therefore, we present data from a large nationwide cohort of patients with osteosarcoma treated at 11 referral centers in Japan during the period 1990–2010 with special reference to survival and relevant prognostic factors. The 3-, 5-, and 10-year metastasis-free survival and overall survival rates for the 529 patients were 70 %, 64 %, and 62 % and 88 %, 83 %, and 77 %, respectively. The prognosis for patients with osteosarcoma in Japan was comparable to, or slightly better than, those reported in other countries. International collaboration should also be conducted in Asian countries including Japan to improve the outcome further and find the optimal treatment for osteosarcoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Rosen G, Marcove RC, Huvos AG, Caparros BI, Lane JM, Nirenberg A, et al. Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy. J Cancer Res Clin Oncol. 1983;106(Suppl):55–67.

    Article  PubMed  Google Scholar 

  2. Eilber F, Giuliano A, Eckardt J, Patterson K, Moseley S, Goodnight J. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol. 1987;5(1):21–6.

    CAS  PubMed  Google Scholar 

  3. Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986;314(25):1600–6. doi:10.1056/NEJM198606193142502.

    Article  CAS  PubMed  Google Scholar 

  4. Link MP, Goorin AM, Horowitz M, Meyer WH, Belasco J, Baker A, et al. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the multi-institutional osteosarcoma study. Clin Orthop Relat Res. 1991;270:8–14.

    PubMed  Google Scholar 

  5. Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23(9):2004–11. doi:10.1200/JCO.2005.06.031.

    Article  CAS  PubMed  Google Scholar 

  6. Harris MB, Cantor AB, Goorin AM, Shochat SJ, Ayala AG, Ferguson WS, et al. Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. Med Pediatr Oncol. 1995;24(2):87–92.

    Article  CAS  PubMed  Google Scholar 

  7. Goorin AM, Schwartzentruber DJ, Devidas M, Gebhardt MC, Ayala AG, Harris MB, et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol. 2003;21(8):1574–80. doi:10.1200/JCO.2003.08.165.

    Article  CAS  PubMed  Google Scholar 

  8. Bacci G, Bertoni F, Longhi A, Ferrari S, Forni C, Biagini R, et al. Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. Cancer. 2003;97(12):3068–75. doi:10.1002/cncr.11456.

    Article  CAS  PubMed  Google Scholar 

  9. Patel SJ, Lynch Jr JW, Johnson T, Carroll RR, Schumacher C, Spanier S, et al. Dose-intense ifosfamide/doxorubicin/cisplatin based chemotherapy for osteosarcoma in adults. Am J Clin Oncol. 2002;25(5):489–95.

    Article  PubMed  Google Scholar 

  10. Wilkins RM, Cullen JW, Odom L, Jamroz BA, Cullen PM, Fink K, et al. Superior survival in treatment of primary nonmetastatic pediatric osteosarcoma of the extremity. Ann Surg Oncol. 2003;10(5):498–507.

    Article  PubMed  Google Scholar 

  11. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20(3):776–90.

    Article  PubMed  Google Scholar 

  12. Crews KR, Liu T, Rodriguez-Galindo C, Tan M, Meyer WH, Panetta JC, et al. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer. 2004;100(8):1724–33. doi:10.1002/cncr.20152.

    Article  CAS  PubMed  Google Scholar 

  13. Iwamoto Y, Tanaka K, Isu K, Kawai A, Tatezaki S, Ishii T, et al. Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J. J Orthop Sci. 2009;14(4):397–404. doi:10.1007/s00776-009-1347-6.

    Article  CAS  PubMed  Google Scholar 

  14. Iwamoto Y, Tanaka K. The activity of the Bone and Soft Tissue Tumor Study Group of the Japan Clinical Oncology Group. Jpn J Clin Oncol. 2012;42(6):467–70. doi:hys059 [pii] 10.1093/jjco/hys059 [doi].

    Article  PubMed  Google Scholar 

  15. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2006;106(5):1154–61. doi:10.1002/cncr.21724 [doi].

    Article  PubMed  Google Scholar 

  16. Grimer RJ, Taminiau AM, Cannon SR. Surgical outcomes in osteosarcoma. J Bone Joint Surg (Br). 2002;84(3):395–400.

    Article  CAS  Google Scholar 

  17. Janeway KA, Barkauskas DA, Krailo MD, Meyers PA, Schwartz CL, Ebb DH, et al. Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children’s Oncology Group. Cancer. 2012;118(18):4597–605. doi:10.1002/cncr.27414 [doi].

    Article  PubMed Central  PubMed  Google Scholar 

  18. Kim MS, Lee SY, Lee TR, Cho WH, Song WS, Koh JS, et al. Prognostic nomogram for predicting the 5-year probability of developing metastasis after neo-adjuvant chemotherapy and definitive surgery for AJCC stage II extremity osteosarcoma. Ann Oncol. 2009;20(5):955–60. doi:mdn723 [pii] 10.1093/annonc/mdn723 [doi].

    Article  CAS  PubMed  Google Scholar 

  19. Smeland S, Muller C, Alvegard TA, Wiklund T, Wiebe T, Bjork O, et al. Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer. 2003;39(4):488–94.

    Article  CAS  PubMed  Google Scholar 

  20. Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM et al. Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alpha-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-1 good response randomized controlled trial. J Clin Oncol. 2015;33(20):2279–87. doi:JCO.2014.60.0734 [pii] 10.1200/JCO.2014.60.0734 [doi].

  21. Whelan JS, Bielack SS, Marina N, Smeland S, Jovic G, Hook JM et al. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. Ann Oncol. 2015;26(2):407–14. doi:mdu526 [pii] 10.1093/annonc/mdu526 [doi].

Download references

Acknowledgments

The authors would like to acknowledge Tsukasa Yonemoto, Shintaro Iwata, Hiroto Kamoda, and Yoko Hagiwara (Chiba Cancer Center); Tomohiro Fujiwara (Okayama University); Eiji Kozawa (Nagoya University); Shigeki Kakunaga (Osaka National Hospital); and Yusuke Shinoda and Yusuke Tsuda (The University of Tokyo Hospital) for data collection and kind assistance.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Akira Kawai .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer Japan

About this chapter

Cite this chapter

Ogura, K. et al. (2016). Outcome of Treatment for Osteosarcoma of the Extremities Over the Last 20 Years: Report from 11 Referral Centers in Japan. In: Ueda, T., Kawai, A. (eds) Osteosarcoma. Springer, Tokyo. https://doi.org/10.1007/978-4-431-55696-1_4

Download citation

  • DOI: https://doi.org/10.1007/978-4-431-55696-1_4

  • Published:

  • Publisher Name: Springer, Tokyo

  • Print ISBN: 978-4-431-55695-4

  • Online ISBN: 978-4-431-55696-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics